['advanced solid tumors']
['anlotinib and 14c-labeled anlotinib']

        Inclusion Criteria:

          -  signed and dated informed consent

          -  histologically or cytologically confirmed diagnosis of advanced solid tumor (including
             RCC、NSCLC、STS and CRC)

          -  failed to the treatment of line 1 or 2

          -  ECOG PS:0-1,Life expectancy of more than 3 months

          -  main organs function is normal

        Exclusion Criteria:

          -  prior treatment with Anlotinib or Allergic to drug or its formulation ingredients

          -  subjects with the gastrointestinal tract, liver and kidney disease of affect drug
             absorption and metabolism

          -  CTCAE(4.0) Grade 1 or higher non-remission toxicity induced by any other previous
             treatments

          -  patients with pleural effusion or ascites, causing respiratory syndrome (CTCAE Grade 2
             or higher dyspnea [Grade 2 dyspnea refers to Shortness of breath with a small amount
             of activities, affecting Instrumental activities of daily life])

          -  patients underwent major surgical treatment，open biopsy or significant traumatic
             injury within 28 days prior to assignment
      